CD226 Antikörper (FITC)

Produktnummer ABIN1449203

Produktdetails anti-CD226 Antikörper (FITC)

Target: CD226

Reaktivität: Human

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser CD226 Antikörper ist konjugiert mit FITC

Applikation: Flow Cytometry (FACS)

Spezifität: This antibody reacts with human CD226/DNAM-1.

Aufreinigung: Protein G agarose

Immunogen: Recombinant human CD226/DNAM-1

Klon: TX25

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: PBS, 0.09 % NaN3, 1 % BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8 °C.

Details zu CD226

Target: CD226

Andere Bezeichnung: CD226 / DNAM1 (CD226 Produkte)

Synonyme: CD226 antikoerper, cd226 antikoerper, zgc:158817 antikoerper, BC051526 antikoerper, DNAM-1 antikoerper, DNAM1 antikoerper, Pta1 antikoerper, TLiSA1 antikoerper, PTA1 antikoerper, CD226 molecule antikoerper, CD226 antigen antikoerper, CD226 antikoerper, cd226 antikoerper, Cd226 antikoerper

Hintergrund: CD226/DNAM-1 (DNAX accessory molecule-1) is a 65 kDa type I transmembrane glycoprotein expressed on the majority of T cells, NK cells, monocytes, and a subset of B-cells. A soluble form (50 kDa) of CD226 is present in normal serum and the supernatant of cultured activated T cells. Ligand binding to CD226 results in phosphorylation of Ser329 and Tyr322, suggesting a role in signal transduction. CD226 acts as an adhesion molecule involved in the binding of certain tumor cells to CTL and NK cells and mediates their cytotoxicity. CD226 also stimulates TNF-α and IFN-γ secretion by alloantigen-specific T cells.Synonyms: DNAM-1, DNAX accessory molecule 1

Gen-ID: 10666

NCBI Accession: NP_006557

UniProt: Q15762

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints